Neuropathic Pain News and Research RSS Feed - Neuropathic Pain News and Research

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments. [More]
Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Mary Ann Liebert, publisher of the newly launched peer-reviewed open access journal Cannabis and Cannabinoid Research, strongly supports President Obama's statement that "...carefully prescribed medical use of marijuana may in fact be appropriate and we should follow the science as opposed to ideology on this issue," when asked about a pending Senate bill seeking to change federal law regarding state-legalized medical marijuana programs. [More]
Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon selection. [More]
FASEB honors Max Planck Florida scientist with Glaxo Smith Kline Neuroscience Discovery Award

FASEB honors Max Planck Florida scientist with Glaxo Smith Kline Neuroscience Discovery Award

The Federation of American Societies for Experimental Biology has honored Samuel M. Young, Jr. Ph.D., a Max Planck Research Group Leader at Max Planck Florida Institute for Neuroscience, with the Glaxo Smith Kline Neuroscience Discovery Award. [More]
Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron. [More]
INS announces winners of inaugural best abstract competition at 12th World Congress

INS announces winners of inaugural best abstract competition at 12th World Congress

The International Neuromodulation Society (INS) announced winners today of its inaugural best abstract competition at the 12th World Congress in Montreal. [More]
International Neuromodulation Society recognizes third Giant of Neuromodulation

International Neuromodulation Society recognizes third Giant of Neuromodulation

The International Neuromodulation Society recognized its third Giant of Neuromodulation at its 12th World Congress in Montreal in June - the first such awardee who is renowned for work in neuromodulation for movement disorder. The honor was given to Prof. Alim-Louis Benabid, MD, PhD, board chairman of the biomedical research center Clinatec in Grenoble. [More]
Weekly sessions of non-invasive brain stimulation improve outcomes in patients with post-stroke pain

Weekly sessions of non-invasive brain stimulation improve outcomes in patients with post-stroke pain

Weekly sessions of non-invasive repetitive transcranial magnetic stimulation provided sufficient long-term pain relief in 61 percent of patients with central post-stroke pain, and delivered long-term relief for patients who continued for one year, according to a study presented at the International Neuromodulation Society 12th World Congress by Masahito Kobayashi, MD, PhD, of the Department of Neurosurgery, Saitama Medical University - Department of Neurology, Institute of Brain and Blood Vessels, Mihara Memorial Hospital in Saitama, Japan. [More]
Duke Medicine scientists produce 3-D map of human brain stem using MRI technology

Duke Medicine scientists produce 3-D map of human brain stem using MRI technology

Scientists at Duke Medicine have produced a 3-D map of the human brain stem at an unprecedented level of detail using MRI technology. [More]
Canadian researchers shed light on molecular dynamics of chronic pain

Canadian researchers shed light on molecular dynamics of chronic pain

Chronic pain affects hundreds of millions of people worldwide and is a major cause of disability, causing more disability than cancer and heart disease. Canadian researchers, including Michael Salter at SickKids are shedding light on the molecular dynamics of chronic pain. They have uncovered a critical role for a class of cells present in the brain and spinal cord, called microglia, in pain. [More]
Scientists find new way to convert blood cells into sensory neurons

Scientists find new way to convert blood cells into sensory neurons

Scientists at McMaster University have discovered how to make adult sensory neurons from human patients simply by having them roll up their sleeve and providing a blood sample. [More]
Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Immune Pharmaceuticals Inc. announced financial results for the first quarter ended March 31, 2015. Immune filed its Quarterly Report on Form 10-Q for the first quarter of 2015 on Friday, May 15, 2015. [More]
Pain management webinar addresses fibromyalgia, "the invisible disease"

Pain management webinar addresses fibromyalgia, "the invisible disease"

Topical BioMedics is hosting its free monthly pain management webinar on Tuesday, May 12th, focusing on the topic “What You need to Know about Fibromyalgia.” The webinar, which is free and open to the public, will be streamed live from 12pm to 1pm, then archived and accessible on demand 24/7... [More]
Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit. [More]
OHTAC recommends MRgHIFU as possible cost-effective strategy for uterine fibroid treatment

OHTAC recommends MRgHIFU as possible cost-effective strategy for uterine fibroid treatment

The Ontario Health Technology Advisory Committee has recommended Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU or MRgFUS) as a possible "cost-effective strategy" and a "safe and effective, noninvasive, uterine-preserving" option for women seeking treatment for uterine fibroids. [More]
New Cannabis and Cannabinoid Research journal to be launched in fall 2015

New Cannabis and Cannabinoid Research journal to be launched in fall 2015

Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. [More]
New brain mapping model could improve success rate of transcranial magnetic stimulation

New brain mapping model could improve success rate of transcranial magnetic stimulation

Brain researchers from the Perelman School of Medicine at the University of Pennsylvania have developed a new brain mapping model which could improve the success rate of transcranial magnetic stimulation (TMS) in treating conditions including depression, neuropathic pain, and stroke. [More]
Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's. [More]
Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. [More]
Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. [More]
Advertisement
Advertisement